Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison

Home, Philip; Boehm, B O; Bott, U.; Behrend, Camilla; Kamp, N M; Lindholm, Anders

doi:10.1016/s0168-8227(00)81585-5

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improved postprandial glucose control and similar HbA 1c values have been shown after 3 months of treatment with BIAsp 30 compared with BHI 30 in type 1 and type 2 diabetic subjects (29). Similar results have been shown for Mix25 in a 6-month randomized trial (18).…”

Section: Conclusion -Glycemic Consupporting

confidence: 67%

Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes

Hermansen¹,

Colombo²,

Storgaard³

et al. 2002

Diabetes Care

122

View full text Add to dashboard Cite

OBJECTIVE—The rapid-acting insulin analogs aspart and lispro have now been developed in biphasic formulations. This trial compared the postprandial serum glucose control of biphasic insulin aspart 30 (BIAsp 30: 30% aspart, 70% protaminated aspart) with that of biphasic insulin lispro 25 (Mix25: 25% lispro, 75% protaminated lispro) and biphasic human insulin 30 (BHI 30: 30% regular insulin, 70% NPH insulin) in insulin-treated subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS—This was an open-labeled, randomized, single-dose, three-way crossover trial of 61 insulin-treated subjects with type 2 diabetes who had no significant late diabetic complications. BIAsp 30 and Mix25 were injected subcutaneously immediately before a test meal, and BHI 30 was injected 15 min before a test meal. The primary target of analysis was serum glucose excursion 0–5 h after a meal. RESULTS—The postprandial glycemic control with BIAsp 30, as assessed by the 5-h postmeal serum glucose excursion, was superior to that with both BHI 30 and Mix25 (16.6 ± 4.5 vs. 20.1 ± 4.9 and 18.9 ± 6.1 mmol/l per hour, respectively; P < 0.001 and P < 0.05). For BIAsp 30 versus BHI 30, this was supported by a reduced maximum glucose concentration [Cmax(SG)] (−5%; P < 0.05) occurring earlier (−13 min; P < 0.01). Furthermore, BIAsp 30 displayed a higher maximum serum insulin concentration (+101%; P < 0.001) occurring earlier (−55 min; P < 0.001) compared with BHI 30. Compared with Mix25, there was a shorter time to Cmax(SG) (−11 min; P < 0.05) after treatment with BIAsp 30. CONCLUSIONS—This trial demonstrates that BIAsp 30 improves postprandial glycemic control compared with both Mix25 and BHI 30 in subjects with type 2 diabetes.

show abstract

Section: Conclusion -Glycemic Consupporting

confidence: 67%

Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes

Hermansen¹,

Colombo²,

Storgaard³

et al. 2002

Diabetes Care

122

View full text Add to dashboard Cite

show abstract

“…Moreover, when dosed 15 min after the start of a meal, BIAsp 30 provided comparable postprandial glucose control to that provided by BHI 30 when dosed 15 min before or immediately before a meal [46]. The flexibility in dosing time with premixed insulin analogues has been shown to have benefits for quality of life in studies of patients with type 1 or type 2 diabetes [48,49]. A 6-month follow-up after 3 months of twicedaily premixed insulin therapy, administered immediately prior to eating (BIAsp 30) or 30 min prior (BHI 30), showed that preference-weighted treatment satisfaction scores were significantly higher for patients who received BIAsp 30 compared with those who received BHI 30 (p < 0.05) [48].…”

Section: Dosing Conveniencementioning

confidence: 98%

“…The flexibility in dosing time with premixed insulin analogues has been shown to have benefits for quality of life in studies of patients with type 1 or type 2 diabetes [48,49]. A 6‐month follow‐up after 3 months of twice‐daily premixed insulin therapy, administered immediately prior to eating (BIAsp 30) or 30 min prior (BHI 30), showed that preference‐weighted treatment satisfaction scores were significantly higher for patients who received BIAsp 30 compared with those who received BHI 30 (p < 0.05) [48]. A 2‐month Japanese study in patients with type 2 diabetes only, yielded similar results: insulin therapy‐related quality of life scores were higher for BIAsp 30 than BHI 30 therapy (100.9 ± 11.7 and 93.1 ± 16.6 respectively; p < 0.05) [49].…”

Section: Dosing Conveniencementioning

confidence: 99%

Premixed insulin treatment for type 2 diabetes: analogue or human?

Garber

Ligthelm

Christiansen

et al. 2006

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

The progressive nature of type 2 diabetes makes insulin initiation a necessary therapeutic step for many patients. Premixed insulin formulations containing both basal and prandial insulin (so called biphasic insulin) are often prescribed because they are superior to long- or intermediate-acting insulin in obtaining good metabolic control. In addition, they are considered as an attractive alternative to classical basal-bolus therapy as fewer daily injections are required. Premixed insulin formulations include conventional (e.g. biphasic human insulin 70/30, or 30/70 in European countries, BHI 30) and newer premixed human analogues (e.g. biphasic insulin aspart 70/30, or 30/70 in Europe, BIAsp 30; insulin lispro mix 75/25-Mix 75/25, or Mix 25/75 in Europe). Like conventional premixed human insulin, premixed insulin analogues contain a fixed proportion of soluble, rapid-acting insulin analogue, with protaminated analogue comprising the remainder. Unlike conventional premixes, analogue premixes have more physiological pharmacokinetic and therapeutically more desirable pharmacodynamic profiles than premixed human insulin. Consequently, postprandial glycaemic control is better with premixed insulin analogues than with premixed human insulin. In nontreat-to-target registration trials, the lowering of haemoglobin A(1c) with premixed insulin analogues was not inferior to that seen with premixed human insulin. Minor hypoglycaemia was similar for premixed analogue and premixed human insulins, while major hypoglycaemia appears to be rare with either formulation. The occurrence of adverse events, other than hypoglycaemia, was also similar between various premix insulins. The premixed insulin analogues, BIAsp 30 and Mix 75/25, like the fast-acting analogues from which they are derived, also allow flexible injection timing, relative to meal timing, thus improving adherence, compliance and quality of life compared with premixed human insulin. Overall, the evidence suggests that premixed insulin analogues are cost effective and have useful advantages over premixed human insulin for the treatment of type 2 diabetes.

show abstract

Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes

Velojic-Golubovic

Mikić

Pešić

et al. 2009

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Treatment with premixed insulin aspart 30 in type 1 and type 2 diabetes: A randomized 12-week comparison

Cited by 5 publications

References 0 publications

Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes

Improved Postprandial Glycemic Control With Biphasic Insulin Aspart Relative to Biphasic Insulin Lispro and Biphasic Human Insulin in Patients With Type 2 Diabetes

Premixed insulin treatment for type 2 diabetes: analogue or human?

Biphasic insulin aspart 30: Better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes

Contact Info

Product

Resources

About